Stammdaten
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
Unternehmen & Branche
| Name | Marker Therapeutics, Inc. |
|---|---|
| Ticker | MRKR |
| CIK | 0001094038 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 15,7 Mio. USD |
| Beta | 1,47 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -12,163,620 | -0.79 | 19,070,997 | 16,796,814 | |
| 2025-09-30 | 10-Q | -1,998,662 | -0.12 | 21,734,830 | 18,388,893 | |
| 2025-06-30 | 10-Q | -4,015,564 | -0.29 | 14,767,870 | 10,490,393 | |
| 2025-03-31 | 10-Q | -4,446,184 | -0.40 | 16,993,266 | 14,491,871 | |
| 2024-12-31 | 10-K | -10,731,315 | -1.19 | 22,022,860 | 18,558,406 | |
| 2024-09-30 | 10-Q | -2,308,192 | -0.26 | 10,910,348 | 7,449,575 | |
| 2024-06-30 | 10-Q | -2,192,677 | -0.25 | 11,675,005 | 9,702,764 | |
| 2024-03-31 | 10-Q | -2,392,822 | -0.27 | 14,091,899 | 11,788,234 | |
| 2023-12-31 | 10-K | -8,236,814 | -0.94 | 17,127,391 | 14,052,543 | |
| 2023-09-30 | 10-Q | -2,981,961 | -0.34 | 19,486,567 | 16,707,103 | |
| 2023-06-30 | 10-Q | 2,515,789 | 0.29 | 21,955,648 | 19,034,752 | |
| 2023-03-31 | 10-Q | -4,967,576 | -0.57 | 27,941,047 | 15,913,348 | |
| 2022-12-31 | 10-K | -29,930,694 | -3.58 | 34,422,184 | 19,601,037 | |
| 2022-09-30 | 10-Q | -6,919,583 | -0.83 | 41,114,565 | 22,601,722 | |
| 2022-06-30 | 10-Q | -9,244,188 | -1.11 | 52,319,738 | 28,026,273 | |
| 2022-03-31 | 10-Q | -9,910,508 | -1.19 | 54,956,134 | 35,705,764 | |
| 2021-12-31 | 10-K | 0 | -41,878,871 | -5.47 | 68,135,134 | 43,985,595 |
| 2021-09-30 | 10-Q | -12,429,323 | -0.15 | 71,939,775 | 52,282,008 | |
| 2021-06-30 | 10-Q | -10,906,782 | -0.13 | 80,470,983 | 63,243,311 | |
| 2021-03-31 | 10-Q | -8,779,450 | -0.16 | 88,362,081 | 72,494,919 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.